Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Leveraging the impact of gut microbes to advance the efficacy of CAR-T cell immunotherapy.

Project description

CAR-T therapy through gut microbiome research

The battle against relapsed or refractory B cell malignancies and myeloma is being transformed by CAR-T cell therapy, a treatment that supercharges the immune system to target cancer. However, this approach faces significant hurdles: its long-term efficacy often diminishes, it can lead to serious toxicities, and it lacks the personalised strategies needed to maximise patient outcomes. A new frontier in addressing these challenges lies in the gut microbiome’s role in boosting CAR-T therapy. In this context, the ERC-funded PowerMiT project aims to uncover how gut and tumour microbiomes, their metabolites, and targeted interventions can enhance CAR-T efficacy, paving the way for safer, more effective cancer immunotherapies tailored to individual needs.

Objective

T cell therapy with chimeric antigen receptor (CAR)-T cells is a curative-intent, transformative treatment aimed to boost antitumor abilities of host T cells against refractory/relapsed B cell malignancies and, recently, against refractory/relapsed myeloma. Major challenges of current CAR-T cell immunotherapies are the loss of long-term efficacy, the occurrence of toxicities including infections, and a lack of personalized patient strategies including biomarkers for response prediction and interventions to enhance CAR-T cell efficacy. This proposal builds on our first evidence for a major role of the gut microbiome in CAR-T cell therapy, and addresses these challenges by presenting a translational research strategy aimed to dissect and leverage the impact of gut microbes in its antitumor efficacy.
In Aim 1, we will investigate the hypothesis that gut and intratumoral microbiome configurations and its metabolites are associated with clinical response of CD19-CAR-T cells in lymphoma, with immunophenotypes of these engineered T cells and the tumor immune microenvironment. We will examine the effects of nutrition and antimicrobial drugs on microbiome features to identify potential mechanisms and therapeutic levers. In Aim 2, we will address the biology of microbiome-CAR-T cell interactions through experimental gut microbiome modulations, and humanizing mice with patient-derived microbial ecologies and individual species and strains in preclinical research models. In Aim 3, we will assess potential therapeutic interventions to increase CAR-T efficacy by investigating the action of microbiome-derived metabolites on CAR-T cells and studying phage- and diet-based interventions to mitigate antibiotic-induced gut microbiome dysbiosis.
Characterising the function of the microbiome and its products in CAR-T immunotherapy harbours an enormous potential to improve current and future T cell transfer therapies for numerous patients suffering from cancer.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Net EU contribution
€ 1 999 819,00
Address
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Germany
Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 819,00

Beneficiaries (1)